These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 26212126)

  • 1. Effect of interferon-β1b on CXCR4-dependent chemotaxis in T cells from multiple sclerosis patients.
    Wostradowski T; Gudi V; Pul R; Gingele S; Lindquist JA; Stangel M; Lindquist S
    Clin Exp Immunol; 2015 Nov; 182(2):162-72. PubMed ID: 26212126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis.
    Weber F; Polak T; Günther A; Kubuschok B; Janovskaja J; Bitsch A; Poser S; Rieckmann P
    Ann Neurol; 1998 Jul; 44(1):27-34. PubMed ID: 9667590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression.
    Reder AT; Velichko S; Yamaguchi KD; Hamamcioglu K; Ku K; Beekman J; Wagner TC; Perez HD; Salamon H; Croze E
    J Interferon Cytokine Res; 2008 May; 28(5):317-31. PubMed ID: 18547162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of interferon-β1b on cytokine patterns of CD4+ and CD8+ T cells derived from RRMS and PPMS patients.
    Skrzipek S; Vogelgesang A; Bröker BM; Dressel A
    Mult Scler; 2012 May; 18(5):674-8. PubMed ID: 22025329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.
    Alexander JS; Harris MK; Wells SR; Mills G; Chalamidas K; Ganta VC; McGee J; Jennings MH; Gonzalez-Toledo E; Minagar A
    Mult Scler; 2010 Jul; 16(7):801-9. PubMed ID: 20621951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo effects of recombinant-interferon-beta1b treatment on polymorphonuclear cell and monocyte functions and on T-cell-mediated antibacterial activity in patients with relapsing-remitting multiple sclerosis.
    Maffione AB; Tatò E; Losito S; Nacci C; Mitolo V; Troiano M; Ruggieri M; Livrea P; Jirillo E
    Immunopharmacol Immunotoxicol; 2000 Feb; 22(1):1-18. PubMed ID: 10737253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
    Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fingolimod reduces CXCR4-mediated B cell migration and induces regulatory B cells-mediated anti-inflammatory immune repertoire.
    Blumenfeld-Kan S; Staun-Ram E; Miller A
    Mult Scler Relat Disord; 2019 Sep; 34():29-37. PubMed ID: 31228713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short communication: treatment of relapsing-remitting multiple sclerosis 96 patients with IFN-beta 1b: results of a 6-year follow-up.
    Bencsik K; Füvesi J; Fricska-Nagy Z; Rajda C; Losonczi E; Török M; Vécsei L
    J Interferon Cytokine Res; 2006 Feb; 26(2):96-100. PubMed ID: 16487029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordant effect of IFN-beta1a therapy on anti-IFN antibodies and thyroid disease development in patients with multiple sclerosis.
    Monzani F; Meucci G; Caraccio N; Saviozzi M; Casolaro A; Moscato G; Lombardo F; Mosti S; Scagnolari C; Bruschi F; Antonelli G; Ferrannini E; Murri L
    J Interferon Cytokine Res; 2002 Jul; 22(7):773-81. PubMed ID: 12184915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo.
    Perini P; Facchinetti A; Bulian P; Massaro AR; Pascalis DD; Bertolotto A; Biasi G; Gallo P
    Eur Cytokine Netw; 2001 Mar; 12(1):56-61. PubMed ID: 11282547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of 1-year treatment with interferon-beta1b on thyroid function and autoimmunity in patients with multiple sclerosis.
    Monzani F; Caraccio N; Meucci G; Lombardo F; Moscato G; Casolaro A; Ferdeghini M; Murri L; Ferrannini E
    Eur J Endocrinol; 1999 Oct; 141(4):325-31. PubMed ID: 10526243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response.
    Carmona O; Casado V; Moral E; Alonso-Magdalena L; Martínez-Yélamos A; Martínez-Yélamos S; Martín-Ozaeta G; Arbizu T
    Eur Neurol; 2008; 60(6):279-84. PubMed ID: 18824855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of CCL27 and IL-11 in Multiple Sclerosis Patients Treated with Interferon-β and Glatiramer Acetate.
    Ebrahimi Monfared M; Shapoori S; Mosayebi G; Khansarinejad B; Ghazavi A; Rezagholizamenjany M; Ganji A
    Neuroimmunomodulation; 2019; 26(6):301-306. PubMed ID: 31935737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin-disaccharide affects T cells: inhibition of NF-kappaB activation, cell migration, and modulation of intracellular signaling.
    Hecht I; Hershkoviz R; Shivtiel S; Lapidot T; Cohen IR; Lider O; Cahalon L
    J Leukoc Biol; 2004 Jun; 75(6):1139-46. PubMed ID: 15020655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Slit-2/Robo-1 modulates the CXCL12/CXCR4-induced chemotaxis of T cells.
    Prasad A; Qamri Z; Wu J; Ganju RK
    J Leukoc Biol; 2007 Sep; 82(3):465-76. PubMed ID: 17565045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of CXCR4 and its down-regulation by IFN-gamma in head and neck squamous cell carcinoma.
    Katayama A; Ogino T; Bandoh N; Nonaka S; Harabuchi Y
    Clin Cancer Res; 2005 Apr; 11(8):2937-46. PubMed ID: 15837745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD45RA+ ICAM-3+ lymphocytes in interferon-beta1b-treated and -untreated patients with relapsing-remitting multiple sclerosis.
    Chatzimanolis N; Kraus J; Bauer R; Engelhardt B; Bregenzer T; Kuehne BS; Tofighi J; Laske C; Stolz E; Blaes F; Voigt K; Traupe H; Kaps M; Oschmann P
    Acta Neurol Scand; 2004 Dec; 110(6):377-85. PubMed ID: 15527450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis.
    Jankovic SM
    J Inflamm Res; 2010; 3():25-31. PubMed ID: 22096354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serial analysis of soluble intercellular adhesion molecule-1 level in relapsing-remitting multiple sclerosis patients during IFN-beta1b treatment.
    Kilinc M; Saatci-Cekirge I; Karabudak R
    J Interferon Cytokine Res; 2003 Mar; 23(3):127-33. PubMed ID: 12716484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.